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Abstract
Background: The TGF family plays a key role in bone homeostasis. Systemic or topic application of proteins of this family
apparently positively affects bone healing in vivo. However, patients with chronic inflammation, having increased TGF-b1
serum-levels, often show reduced bone mineral content and disturbed bone healing. Therefore, we wanted to identify
intracellular mechanisms induced by chronic presence of TGF-b1 and their possible role in bone homeostasis in primary
human osteoblasts.
Methodology/Principal Findings: Osteoblasts were isolated from femur heads of patients undergoing total hip
replacement. Adenoviral reporter assays showed that in primary human osteoblasts TGF-b1 mediates its signal via
Smad2/3 and not Smad1/5/8. It induces proliferation as an intermediate response but decreases AP-activity and inorganic
matrix production as a late response. In addition, expression levels of osteoblastic markers were strongly regulated (APQ;
OsteocalcinQ; Osteopontinq; MGPQ; BMP 2Q; BSP2Q; OSF2Q; OsteoprotegerinQ; RANKLq) towards an osteoclast
recruiting phenotype. All effects were blocked by inhibition of Smad2/3 signaling with the Alk5-Inhibitor (SB431542).
Interestingly, a rescue experiment showed that reduced AP-activities did not recover to base line levels, even 8 days after
stopping the TGF-b1 application.
Conclusions/Significance: In spite of the initial positive effects on cell proliferation, it is questionable if continuous Smad2/3
phosphorylation is beneficial for bone healing, because decreased AP-activity and BMP2 levels indicate a loss of function of
the osteoblasts. Thus, inhibition of Smad2/3 phosphorylation might positively influence functional activity of osteoblasts in
patients with chronically elevated TGF-b1 levels and thus, could lead to an improved bone healing in vivo.
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Introduction
Throughout life, bone undergoes continuous remodeling by a
coordinated process of bone formation and bone resorption. Bone
is formed by osteoblasts, which are of mesenchymal origin, and is
resorbed by osteoclasts, derived from the hematopoietic system.
Both actions are closely linked to maintain constant bone mass in
the adult skeleton. Deregulation of this balance underlies the
pathological loss of bone mass seen with delayed bone healing after
fracture, osteoporosis and other metabolic bone diseases. Despite
of their importance for our understanding of normal bone
metabolism and the pathogenesis of metabolic bone diseases, the
molecular mechanisms that govern the coordination of these
processes are largely unknown.
Bone morphogenic proteins (BMPs), members of the trans-
forming growth factor-b (TGF-b) superfamily, are able to
promote osteogenesis, chondrogenesis and adipogenesis, whereas
they inhibit myogenesis of mesenchymal progenitor cells [1].
However, as TGF-b is by far the most abundant cytokine in
bone, by its mere abundance (200 mg/kg), it must be considered
as a central player in bone turnover [2]. Both osteoblasts and
osteoclasts secrete all three TGF-b iso-forms (TGF-b1,- b2 and -
b3), which are present in their latent form within bone matrix
[3,4]. During bone turnover, acidification of the resorption
lacuna by osteoclasts is thought to activate TGF-b [5], which
should then stimulate the formation of bone [6]. Systemic or
topic application of proteins of this family apparently positively
affects bone healing in vivo. However, TGF-b is also strongly
expressed during various inflammation reactions. Patients with
liver fibrosis or cirrhosis often show elevated TGF-b levels over a
long period [7,8]. Similar results are seen in cardiac fibrosis,
chronic renal failure or fibrosis of other tissues [9,10,11]. Thus,
we propose that chronically increased serum levels of TGF-b1
observed in many systemic diseases might be a potential inducer
for associated loss of bone density, as seen in hepatic or renal
osteodystrophy.
Members of the TGF-b superfamily transduce their signals
through two types of serine/threonine kinase receptors, termed
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14073type I and type II [12,13]. The type II receptors are constitutively
active kinases which phosphorylate type I receptors upon ligand
binding. Seven type I receptors termed activin receptor-like kinase
(Alk)-1 through -7 have been identified in mammals. BMPs,
activins and TGF-b1–3 bind to different type I receptors,
depending on the cell type. BMPs preferably bind to Alk2, -3
and -6, whereas activins and TGF-b1–3 bind to Alk-4 and Alk-5,
respectively. Upon activation by type II receptors, Alks activate
(phosphorylate) transcription factors, so-called Smads, in the
cytoplasm. Eight different Smads have been identified in
mammals. They are classified into three groups: receptor-
regulated Smads (R-Smads/Smad1, -2, -3, -5 and -8), inhibitory
Smads (I-Smads/Smad6 and-7) and the common-partner Smad
(Co-Smad/Smad4). Alk1, -2, -3 and -6 activate Smad1/5/8 while
Alk4, -5 and -7 activate Smad2/3 [14]. Upon activation Smad1/
5/8 and Smad2/3 form complexes with Smad4, which allows
them to translocate into the nucleus for regulation of target gene
expression [15]. The signaling cascade of Smad2/3 can be
inhibited by the chemical inhibitor SB431542, which has been
shown to inhibit Alk4, -5, and -7 kinase activity specifically, but
not Alk2, -3, and -6 kinase activity [16].
TGF-b1 is a multifunctional signaling protein that initiates a
wide variety of responses in many different cell types. Thus, TGF-
b1 is involved in embryogenesis, differentiation, wound healing,
extracellular matrix (ECM) production and cell-cell adhesion
[17,18,19]. Osteoblasts express a large variety of high affinity
TGF-b receptors and therefore, TGF-b is thought to regulate
many osteoblastic functions including expression of ECM genes,
e.g. collagen and fibronectin, their integrin receptors and even the
stabilization of integrin subunits [4,20,21,22]. From the TGF-b
superfamily, TGF-b1 showed the strongest chemotactic effect
towards human osteoblasts, thus application of this cytokine in a
dog model was able to enhance mechanical fixation, bone
ingrowth and gap bone formation with unloaded implants
surrounded by a gap. This effect was pronounced only with low
concentrations of TGF-b1 but not with higher concentrations [23].
In vitro effects of TGF-b vary substantially depending upon the cell
system. Neonatal and fetal organ cultures have generally indicated
that TGF-b inhibits osteoclast differentiation from bone marrow
monocytes, yet stimulates bone resorption by differentiated
osteoclasts [24,25]. From these results it is hard to draw
conclusions for the normal role of TGF-b in bone development.
Besides its complex and variable effects on bone cell populations in
vitro and in vivo, a given experimental result with TGF-b may be
potentially relevant to many different aspects of skeletal morpho-
genesis, including the generation of bone shape, bone growth, or
bone remodeling. Thus, aim of this study was to investigate the
long term effects of TGF-b1 on primary human osteoblasts in
terms of signaling, proliferation, alkaline phosphatase (AP) activity,
osteogenic marker gene expression and mineralized matrix
formation.
Results
TGF-b1 increases proliferation but decreases AP activity
in primary human osteoblasts
Primary human osteoblasts were treated with different conc. (0,
1, 2.5, 5, 10 ng/ml) of human recombinant active (hra) TGF-b1.
After 8 days AP-activity was measured and adherent cells were
fixed for SRB staining of surface proteins. SRB staining confirmed
the microscopical observation that TGF-b1 induces proliferation
in primary human osteoblasts in a dose dependent manner
(Figure 1A). At the same time AP-activity was significantly
reduced, dose-dependently (Figure 1B).
TGF-b1 mediates its signal via Smad2/3 in primary human
osteoblasts
Primary human osteoblasts were infected with adenoviral
reporter constructs (Ad5-CAGA9-MLP-Luc or Ad5-BRE-Luc) as
described in materials and methods. After infection, cells were
stimulated with 5 ng/ml hra TGF-b1. Cell lysates were taken after
24 h (Ad5-CAGA9-MLP-Luc) or 48 h (Ad5-BRE-Luc) and
luciferase activity was measured. TGF-b1 increased only Smad3
regulated luciferase signal (Ad5-CAGA9-MLP-Luc) by 9.3-fold.
Induction was completely inhibited by the Alk5 inhibitor
SB431542, in a dose-dependent manner (Figure 2A). In contrast
to BMP2 (1.9760.18 fold; p,0.001) or BMP7 (2.2460.21 fold;
p,0.001), hra TGF-b1 was not able to induce Smad1 dependent
luciferase expression.
Increased proliferation and decreased AP-activity by TGF-
b1 is dependent on Smad2/3 signaling and can be
reversed by Alk5 inhibitor SB431542
Primary human osteoblasts were stimulated with 5 ng/ml hra
TGF-b1 with or without different conc. of Alk5 inhibitor
SB431542 (5, 10, 20, 40 nM) for 8 days. Cells were also infected
with adenoviral constructs expressing constitutive active Alk5
(Ad5-caAlk5) for 4 days. In this setting, the constitutive active Alk5
ensures activation of the Smad2/3 pathway without additional
stimulation with TGF-b1. AP-activity was measured and adherent
cells were fixed for SRB staining of surface proteins. SRB showed
that TGF-b1-dependent induction of proliferation in primary
human osteoblasts can be inhibited by the Alk5 inhibitor
SB431542 in a dose-dependent manner. Infection of cells with
caAlk5 also led to increased SRB staining (Figure 2B). Interest-
ingly, SB431542 not only inhibited the reduction of AP-activity,
but even seemed to increase AP-activity dose-dependently
(Figure 2C).
Reversal of TGF-b1-dependent effects on AP-activity by
SB431542 is time-dependent
Primary human osteoblasts were stimulated with 5 ng/ml hra
TGF-b1 with or without 20 nM Alk5 inhibitor SB431542. After 4,
8 and 12 days of continuous stimulation with TGF-b1 AP activity
was measured for half of the cells. The other half of the cells was
washed twice with DPBS and culturing was continued for 8 days
with basic culture medium. After the additional 8 days AP activity
was measured again. With increasing time AP-activity was further
reduced by TGF-b1 treatment. For all time-points the Alk5
inhibitor SB431542 was able to block the TGF-b1-dependent
decrease of AP activity. With increasing time of TGF-b1 pre-
treatment, the so-called ‘‘rescue effect’’, observed after the
additional 8 days in basic culture medium, was reduced
(Figure 3A–C).
TGF-b1 inhibits formation of mineralized matrix in
primary human osteoblasts
During osteogenic differentiation primary human osteoblasts
were stimulated with 5 ng/ml hra TGF-b1 in the presence or
absence of 20 nM Alk5 inhibitor SB431542. After 20 days
mineralized ECM was stained with Alizarin Red or von Kossa.
Von Kossa staining showed that constant treatment of primary
human osteoblasts with TGF-b1 inhibited production of mineral-
ized matrix (Figure 4A). Alizarin Red staining revealed that
formation of mineralized matrix was reduced to 49.168.1% of
control cells. This effect was partially reversed (81.968.0%) by the
Alk5 inhibitor SB431542 (Figure 4B).
TGF-b1 Inhibits Osteoblasts
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supernatant
RANKL levels in culture supernatants of human osteoblasts
(N=3, n=4), stimulated for 8 days with 5 ng/ml hra TGF-b1
with or without 20 nM Alk5 inhibitor SB431542, were measured
by ELISA. TGF-b1 increased RANKL secretion by 2.2260.12
fold (p,0.001). Stimulation with SB431542 alone did not
significantly alter RANKL levels in the culture supernatant
(0.0460.07 fold of control). However, SB431542 was able to
significantly reduce the TGF-b1-dependant increase in RANKL
secretion by 66.762.7% (p,0.001).
TGF-b1 regulates expression of osteoblast marker genes
Primary human osteoblasts were stimulated with 5 ng/ml hra
TGF-b1 with or without 20 nM Alk5 inhibitor SB431542. At the
same time cells were infected with Ad5-caAlk5 virus particles.
After 8 days we isolated mRNA for expression analysis. RT-PCRs
were performed for AP, collagen1 (Col1), osteocalcin (OC),
osteopontin (OP), osteonectin (ON), BMP2, bone sialoprotein
(BSP) 2, matrix gla protein (MGP), osteoblasts specific factor (OSF)
2 and osteoprotegerin (OPG). GAPDH was used as housekeeping
gene (Figure 5). Densitometric analysis (Table 1) showed that
TGF-b1 treatment reduced AP mRNA levels compared to
Figure 1. TGF-b1 increases proliferation but decreases AP activity in cultured osteoblasts. Primary human osteoblasts were treated for 8
days with different conc. (0, 1, 2.5, 5, 10 ng/ml) of hra TGF-b1. (A) SRB staining of surface proteins showed that TGF-b1 dose-dependently increased
proliferation of osteoblasts. (B) In contrary, AP activity, normalized to relative cell numbers, was decreased by TGF-b1 in a dose-dependent manner.
Results are expressed as mean 6 standard deviation (N=4, n=4). **p,0.01, ***p,0.001 in comparison to untreated cells.
doi:10.1371/journal.pone.0014073.g001
Figure 2. TGF-b1 mediated changes in primary human osteoblasts are Smad2/3-dependent. (A) Primary human osteoblasts (N=4, n=3)
infected with Ad5-CAGA9-MLP-Luc reporter constructs (Smad2/4 reporter) were stimulated with 5 ng/ml hra TGF-b1 in the presence or absence of the
Alk5 inhibitor SB431542 (5, 10, 20 and 40 nM). After 24 h luciferase activity was measured in cell lysates and normalized to total protein contents. (B/
C) Primary human osteoblasts (N=4, n=4) were stimulated with 5 ng/ml hra TGF-b1 with or without the SB431542 (5, 10, 20, 40 nM) for 8 days or
infected with Ad5-caAlk5 for 4 days. (B) Both TGF-b1 stimulation and caAlk5 infection increased proliferation (SRB staining) in primary human
osteoblasts, which was inhibited dose-dependently by SB431542. (C) In the same line, AP activity, normalized to relative cell numbers, was decreased
by TGF-b1 stimulation and infection with caAlk5. The decrease in AP-activity was blocked by SB431542 in a dose-dependent manner. Results are
expressed as mean 6 standard deviation. **p,0.01, ***p,0.001 in comparison to only TGF-b1 treated cells.
doi:10.1371/journal.pone.0014073.g002
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In addition, expression levels of BMP2 and OSF2, involved in
osteoblasts recruitment and adhesion, were reduced by TGF-b1
treatment and Ad5-caAlk5 infection. Col1 and ON mRNA levels
were not significantly altered. Genes involved in matrix mineral-
ization, e.g. OC, BSP and MGP, were significantly down-
Figure 3. TGF-b1 dependent effects on AP activity by SB431542 are depending on time. Primary human osteoblasts stimulated with 5 ng/
ml hra TGF-b1 in the presence or absence of 20 nM SB431542. After (A) 4, (B) 8 and (C) 12 days of continuous stimulation with TGF-b1 AP activity was
measured and normalized to SRB staining for half of the cells (empty bars). The remaining cells were washed twice with DPBS and continued
culturing for 8 days with basic culture medium. After the additional 8 days AP activity was measured in the same way (filled bars). Overall, with
increasing time AP-activity was more and more reduced in the presence of TGF-b1. Supplementation with SB431542 was able to block the TGF-b1-
dependent decrease of AP activity at all time-points. However, with increasing time of TGF-b1 pre-treatment, the so-called ‘‘rescue effect’’, observed
after the additional 8 days in basic culture medium, was reduced. Results are expressed as mean 6 standard deviation (N=4, n=4). *p,0.05,
**p,0.01, ***p,0.001 versus the corresponding untreated cells.
doi:10.1371/journal.pone.0014073.g003
Figure 4. TGF-b1 inhibits formation of mineralized matrix in primary human osteoblasts. Primary human osteoblasts cultured in
differentiation medium with 5 ng/ml hr TGF-b1 with or without 20 nM SB431542 for 20 days. (A) Representative picture for von Kossa staining for
mineralized matrix. (B) Quantitative staining of produced mineralized matrix with Alizarin Red. Continuous stimulation of cells with TGF-b1 inhibited
formation of mineralized matrix. We could prevent this effect by addition of SB431542. Results are expressed as mean 6 standard deviation (N=5,
n=6). ***p,0.001 in comparison to control conditions.
doi:10.1371/journal.pone.0014073.g004
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which favors osteoclast binding is increased by stimulation with
TGF-b1 and over-expression of caAlk5. In the same line, mRNA
levels of OPG, inhibiting osteoclast differentiation and activity,
were reduced by both treatments. All observed effects were
reversed by co-incubation with the Alk5 inhibitor SB431542.
TGF-b1 reduces BMP2 and BMP7 mediated Smad1/5/8
signaling in human osteoblasts
Primary human osteoblasts were infected with Ad5-BRE-Luc
adenoviral particles (Smad1/4 reporter construct) and stimulated
with 5 ng/ml hra TGF-b1 and/or 50 ng/ml hra BMP2 or -7. Cell
lysates were taken after 48 h and luciferase activity was measured.
In contrast to BMP2 (2.060.2 fold) and BMP7 (2.260.2 fold),
TGF-b1 failed to induce Smad1 regulated luciferase signal.
Interestingly, BMP2 and -7 induced luciferase signal was blocked
by co-incubation with TGF-b1 (Figure 6).
Discussion
TGF-b is secreted by bone cells and therefore bone represents
one of the biggest reservoirs for all three TGF-b iso-forms (TGF-
b1,- b2 and -b3) of the human body. However, in bone matrix they
are present in their latent form [4]. During bone resorption by
osteoclasts, pH is decreased and this acidification is thought to
activate the TGF-b reservoir which should then stimulate the
formation of bone [5]. However, patients with chronic inflamma-
tion, often have constantly increased active TGF-b1 levels due to
macrophage activation at the inflammation site. The distribution
of this growth factor throughout the body via the bloodstream
might influence other organs.
As osteoblasts contain a large variety of high affinity TGF-b1
receptors, TGF-b1 is thought to regulate many osteoblastic
functions including expression of ECM genes, e.g. collagen and
fibronectin, and the corresponding integrin receptors [4,20,21,22].
Furthermore, it has been suggested that the down-regulation of
cytokines and hormones, such as IGF-1, IL-11 and growth
hormone, but also TGF-b1, is correlated with age related bone
loss [26,27,28]. This hypothesis was supported by in vitro studies
showing that TGF-b increases synthesis of type I collagen and
non-collagenous bone proteins by cultured osteoblastic cells
[2,17,29]. However, in our set-up of continuous TGF-b1
stimulation type I collagen mRNA did not alter. Moreover,
matrix mineralization was blocked completely. In contrary, in vivo
TGF-b1 knockout mice display a decrease of about 30% in tibia
length and a reduction in bone mineral content [30], indicating
the need for TGF-b1 in bone formation. Furthermore, local
injection of TGF-b1 under the periosteum stimulated cartilage and
bone formation [6,31] while systemic injection of TGF-b2 leads to
a general increase in osteoblastic activity [32]. In contrast,
transgenic mice with osteoblasts specific (osteocalcin promoter)
over-expression of TGF-b2 show a dramatic, age-dependent loss of
bone mass similar to that seen in osteoporosis and hyperparathy-
roidism [33]. Furthermore, transgenic mice over-expressing
osteoblast specific cytoplasmically truncated type II TGF-b
receptor show decreased bone remodeling and increased trabec-
ular bone mass with tougher femurs and stiffer and stronger
vertebral bodies [34]. Similar results were observed when TGF-b
type I receptor kinase was pharmacologically inhibited by SD-208.
These mice showed increased bone mass and multiple aspects of
bone quality as trabecular bone architecture and macro-
mechanical behavior of vertebral bone [35]. Due to these, often
Figure 5. TGF-b1 regulates expression of osteoblast marker
genes. Primary human osteoblasts (N=4), stimulated for 8 days with
5 ng/ml hr TGF-b1 with or without 20 nM SB431542 or infected with
Ad5-caAlk5 virus particles, were investigated for expression of
osteogenic marker genes by RT-PCR. alkaline phosphatase (AP),
collagen1 (Col1), osteocalcin (OC), osteopontin (OP), osteonectin (ON),
BMP2, bone sialoprotein (BSP) 2, matrix gla protein (MGP), osteoblasts
specific factor (OSF) 2 and osteoprotegerin (OPG). GAPDH was used as
housekeeping gene. Ø negative control (H2O) Corresponding densito-
metric analysis is summarized in Table 2.
doi:10.1371/journal.pone.0014073.g005
Table 1. Densitometric analysis of RT-PCR.
Gene Control 5 ng/ml TGF-b1 5 ng/ml TGF-b1 20 nM SB431542 Ad5-caAlk5
AP 1.0060.11 0.3960.05 0.9460.10 0.6260.08
BMP2 1.0060.16 0.5760.21 1.1160.13 0.3760.04
OSF2 1.0060.14 0.5860.13 0.8560.13 0.7660.11
Col1 1.0060.12 0.8660.12 0.9160.12 0.8860.08
OC 1.0060.16 0.4060.06 1.0260.17 0.5160.11
ON 1.0060.19 1.0060.19 1.2760.24 1.1660.22
BSP2 1.0060.14 0.2260.03 1.6160.25 0.4760.09
MGP 1.0060.10 0.8360.10 1.3860.19 0.6560.07
OP 1.0060.08 1.3460.28 0.7260.09 1.1760.08
OPG 1.0060.08 0.5160.04 1.0860.11 0.2660.05
N=4, n=5.
doi:10.1371/journal.pone.0014073.t001
TGF-b1 Inhibits Osteoblasts
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primary human osteoblasts regarding proliferation, AP-activity,
formation of mineralized matrix and osteogenic marker gene
expression during a culture period of 20 days, thereby focusing on
the underlying signaling cascades and mechanisms. Osteoblasts
were isolated from femoral heads of patients undergoing total hip
replacement. The average age of the patients was 75.25 years,
which resembles the age of patients having an increased incidence
of fractures because of loss of bone mineral density due to systemic
disorders. In order to perform the experiments with a homoge-
neous population of primary osteoblasts we cultured and expanded
our cells until passage 3 or 4 (up to 4 month) under standard
culture conditions. Thus, the addition of TGF-b1 resembles the
conditions observed in patients with chronic inflammation. During
the first days TGF-b1 strongly induced proliferation of primary
human osteoblasts. One possible mechanism might be an
interaction between TGF-b1 signaling and Ras activation with
subsequent stimulation of MAPKinases ERK, p38 and JNK [36].
This is supported by the in vivo findings showing that exogenously
administered recombinant TGF-b was able to increase bone
formation and to promote fracture healing [37]. TGF-b1, as well
as PDGF-BB, showed the strongest chemotactic effects towards
human osteoblasts and thus was able to enhance mechanical
fixation, bone ingrowth and gap bone formation in a dog model
with unloaded implants surrounded by a gap. Noteworthy, this
effect was only present with low concentrations of TGF-b1 but did
not appear any more with higher concentrations of this cytokine
[23]. This is supported by our results showing that, although the
observed increase in proliferation was more pronounced with
increasing TGF-b1 concentrations, AP activity and formation of
mineralized matrix was dose-dependently reduced. This effect was
not only dose- but also time-dependent. Thus, a ‘‘rescue’’
experiment, documenting AP activity, showed that cells could
not recover completely from TGF-b1 stimulation for more than 8
days. Thus, in patients with chronic inflammation, having
significantly increased levels of circulating TGF-b1 for up to
several years [7,8], this might be a key regulator for reduced bone
mineralization. Moreover, mRNA analysis revealed that gene
expression of treated osteoblasts was shifted from osteoblasts
maturation to osteoclast recruitment after only 8 days. For
example osteopontin, favoring osteoclast binding, was induced
by TGF-b1 in our cell system. Furthermore, we could show a
significant increase in RANKL secretion when TGF-b1 is used as
stimulus. At the same time OPG, an inhibitor for osteoclast
differentiation and activity, was down-regulated in primary human
osteoblasts. In contrast, in stromal cells TGF-b1 is reported to
stimulate OPG and other factors that indirectly inhibit osteoclas-
togenesis [38]. Thus, it is conceivable that endogenous TGF-b is in
the initial step essential for osteoclastogensis induced by a
combination of receptor activator of NF-kB ligand (RANKL)
and M-CSF [39]. Interestingly, TGF-b1 did not significantly alter
Col1 expression in our experiments, but all genes involved in
matrix mineralization, explaining the results observed by von
Kossa and Alizarin Red staining for mineralized matrix. The
observed effects of TGF-b1 could be inhibited by SB431542,
which has been shown to inhibit ALK-4/5/7 kinase activity
specifically, but not ALK2/3/6 kinase activity responsible for
BMP signaling via Smad1/5/8 [16]. Therefore, we propose that
the functional loss of osteoblast activity by TGF-b1 treatment is
mediated via Smad2/3 signaling. This is supported by our findings
that over-expression of constitutive active Alk5 induced similar
effects as TGF-b1 in primary human osteoblasts. As expression of
caAlk5 is independently of receptor binding activating Smad2/3
phosphorylation, our data clearly suggest that the observed effects
are mediated by Smad2/3 signaling. Analysis of possible signaling
cascades by adenoviral reporter assays revealed that TGF-b1 only
activated Smad2/3 signaling but not Smad1/5/8 signaling as
BMP2 or -7. Interestingly, BMP-mediated Smad1/5/8 signaling
was reduced by TGF-b1 co-incubation, which might be an
explanation for the observed functional loss of the osteoblasts. One
possible mechanism for this inhibition might be increased
expression of Smad6, as observed in TGF-b stimulated C2C12
cells [40].
As bone repair is one of the most important and urgent subjects
for our over-aging society, members of the TGF-b superfamily,
e.g. TGF-b1 and BMPs, are expected to be applied to the
treatment of various orthopedic diseases including bone fracture
and spinal fusion [18,41]. Cell adhesion is the first crucial step for
osseointegration as it specifies the fate of the cell. Furthermore,
proliferation, differentiation, ECM production and organization as
well as apoptosis are influenced by the events of cell-substrate
adhesion [42,43,44]. However, as described before, effects of
TGF-b vary substantially depending upon the cell system. While
in neonatal and fetal organ culture TGF-b generally inhibited
osteoclast differentiation from bone marrow monocytes, it
stimulated bone resorption by differentiated osteoclasts [24,25].
The normal role of TGF-b in bone development has been hard to
infer from these studies. Besides its complex and variable effects on
bone cell populations in vitro and in vivo, the exogenous application
of TGF-b does not mimic its route of production within bone,
where it is produced and stored largely as a bone matrix-bound
latent complex that may be unable to induce cellular responses
unless first released from mineralized bone during osteoclastic
bone resorption [45]. TGF-b is strongly expressed during various
inflammation reactions. Patients with liver fibrosis or cirrhosis
often show elevated TGF-b levels [7,8]. Similar results are seen in
cardiac fibrosis, chronic renal failure or fibrosis of other tissues
[9,10,11]. Thus, we propose that chronically increased serum
levels of TGF-b1 observed in many systemic diseases might be a
potential inducer for associated loss of bone density, as seen in
hepatic or renal osteodystrophy. Thus, understanding the
underlying mechanisms is mandatory to provide future possible
therapeutic concepts for delayed fracture healing and metabolic
Figure 6. TGF-b1 suppresses BMP2 and BMP7 mediated Smad1/
5/8 signaling in osteoblasts. Primary human osteoblasts infected
with Ad5-BRE-Luc adenoviral particles (Smad1/4 reporter) were
stimulated with 5 ng/ml hr TGF-b1 and/or 50 ng/ml hr BMP2 or -7.
After 48 h luciferase activity was measured in cell lysates and
normalized to total protein contents. BMP2 and -7 significantly induced
Smad1/4 reporter signal by more than 2 fold. TGF-b1 showed now
Smad1/4 reporter signal. Furthermore, in co-stimulation TGF-b1 even
inhibited the observed BMP2 and -7 mediated Smad1/4 signaling.
Results are expressed as mean 6 standard deviation (N=3, n=6).
***p,0.001 versus untreated cells. uuup,0.001.
doi:10.1371/journal.pone.0014073.g006
TGF-b1 Inhibits Osteoblasts
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and in vivo experiments administered TGF-b only for short times,
which precludes an evaluation of the skeletal actions of TGF-b at
steady state. Our study showed that despite the initial induction of
proliferation, continuous stimulation of osteoblasts with TGF-b1
led to a functional loss which is Smad2/3-dependent. This
knowledge opens new perspectives for investigation and treatment
of delayed bone healing or metabolic bone diseases. For example
local growth factor application to improve osteointegration can
only be successful, if this initial recruiting and proliferation of
osteoblasts does not interfere with BMP signaling as observed in
the present experimental setup, representing constantly increased
active TGF-b levels present in serum of patients with chronic
inflammation, which is associated with functional loss of
osteoblasts or osteoclast recruitment.
Materials and Methods
Human recombinant active TGF-b1 (Peprotech, London, UK);
Cell Culture Medium and supplements (PAA, Co ¨lbe, Germany);
Chemicals were obtained from Sigma (Munich, Germany).
Ethics Statement
Osteoblasts were isolated from femur heads of patients
undergoing total hip replacement, in accordance to the ethical
vote of the MRI (‘‘Ethikkommission der Fakulta ¨t fu ¨r Medizin der
Technischen Universita ¨t Mu ¨nchen’’, http://www.ek.med.tum.de,
Project Number 2413, TU Munich, Germany) and the patients’
written consent. Bone tissue from (potential) tumor patients or
patients with viral or bacterial infections was excluded from the
study.
Isolation and culture of primary human osteoblasts
We obtained femur heads from 8 patients (7 female, 1 male)
with an average age of 75.25 years. Briefly, cancellous bone was
removed mechanically from the femur head, washed 3–5 times
with DPBS followed by 1 h incubation at 37uC with an equal
volume of digestion buffer (DPBS, 0.07% Collagenase II –
Biochrom AG, Berlin, Germany). After digestion, cancellous bone
was washed with DPBS and transferred to cell culture flasks in
culture medium (MEM/Ham’s F12, 10% FCS, 2 mM L-
glutamine, 100 U/ml penicillin, 100 mg/ml Streptomycin,
50 mM L-ascorbate-2-phosphate, 50 mM b-glycerol-phosphate).
Medium was changed every 4–5 days. Within two weeks cells were
growing out of the bone pieces [43,46]. Osteoblasts were cultured
and expanded until passage 3, where a pure population of
osteoblasts was reached, as determined by flow cytometry,
negative for CD14 and CD45 and positive for CD90 and
CD105. Only cells in passage 3 and 4 were used for the
experiments. For differentiation, cells were cultured for up to 20
days with differentiation medium (MEM/Ham’s F12, 5% FCS,
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml Streptomy-
cin, 100 mM L-ascorbate-2-phosphate, 10 mM b-glycerol-phos-
phate, 25 mM HEPES, 1.5 mM CaCl2, 100 nM Dexametha-
sone). Medium was changed every 4
th day.
Transient Cell Infections and Reporter Gene Assays
Cells were infected with the Smad1/4 reporter adenovirus
(Ad5-BRE-Luc/provided from Prof. P. ten Dijke) or the Smad3/4
reporter adenovirus (Ad5-CAGA9-MLP-Luc) as described before
[47]. Upon binding of phosphorylated Smad1/4 or Smad3/4,
respectively, luciferase if expressed in the cytoplasm of the cells.
Cell lysates and luciferase activity measurement was done
according to the manufacturer’s instructions, using the Steady-
Glo Luciferase Assay System (Promega, Madison, USA) and
normalized to total protein content.
Furthermore, we infected cells with adenoviral particles
resulting in the expression of constitutive active Alk5 (Ad5-
caAlk5), to investigate TGF-b effects independent of substrate
binding. The expressed Alk5 is genetically modified in a way to
constitutively activate Smad2/3 phosphorylation and associated
signaling.
Infection efficiency was shown to be .90% by fluorescent
microscopy of cells infected with Ad5-GFP (24 h).
Alkaline Phosphatase (AP) Activity Measurement
Prior to substrate incubation with pNPP buffer (0.2% 4-
nitrophenyl-phosphate disodium salt hexahydrate, 50 mM glycine,
1 mM MgCl2, 100 mM TRIS, pH 10.5) for 1 h, cells were
washed with DPBS. Resulting formation of 4-nitrophenol (pNP),
was determined photometrically at 405 nm. Signal was normal-
ized to relative cell number determined by Sulforhodamine (SRB)
staining as reported [48].
Table 2. Summary of PCR conditions.
Gene
GeneBank
accession
[NM_] Forward Primer 59-39 Reverse Primer 59-39 Tm [uC]
Product
length
[bp]
AP 000478.3 ACG TGG CTA AGA ATG TCA TC CTG GTA GGC GAT GTC CTT A 53 476
Col1 000088.3 CAG CCG CTT CAC CTA CAG C TTT TGT ATT CAA TCA CTG TCT TGC C 56 84
OC 199173.3 CCA.GCG.GTG.CAG.AGT.CCA.GC GAC.ACC.CTA.GAC.CGG.GCC.GT 56 236
OP 000582 CTC CAT TGA CTC GAA CGA CTC CGT CTG TAG CAT CAG GGT ACT G 60 257
ON 003118 AGC ACC CCA TTG ACG GGT A GGT CAC AGG TCT CGA AAA AGC 60 105
BMP2 001200 CCC CCT ACA TGC TAG ACC TGT CAC TCG TTT CTG GTA GTT CTT CC 60 150
BSP2 004967 TGA CTC ATC CGA AGA AAA TGG AG CTG GAT TGC AGC TAA CCC TGT 60 202
MGP 000900 AGA TGG AGA GCT AAA GTC CAA GA GTA GCG TTC GCA AAG TCT GTA 60 102
OSF2 006475 TAA GTT TGT TCG TGG TAG CAC C GTG TGG GTC CTT CAG TTT TGA TA 60 140
OPG 002546.3 CCG GAA ACA GTG AAT CAA CTC AGG TTA GCA TGT CCA ATG TG 60 313
GAPDH 002046.3 GTC AGT GGT GGA CCT GAC CT AGG GGT CTA CAT GGC AAC TG 54 420
doi:10.1371/journal.pone.0014073.t002
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Prior to fixation of cells with 100% ice cold ethanol ($1 h), cells
were washed with DPBS. Briefly, ethanol was removed by washing
cells 3 times with tab water. For von Kossa staining cells were
covered with staining solution (3% silver-nitrate) for 30 min at RT.
To remove excessive staining solution, cells were washed 3 times
with tab water. For color development (brownish-black) cells were
covered with sodium-carbonate-formaldehyde solution (0.5 M
sodium-carbonate, 10% formaldehyde). Pictures were taken with
an inverted microscope. For Alizarin Red staining cells were
covered with staining solution (0.5% alizarin red, pH=4.0) for
30 min at RT. Excessive staining solution was removed by
washing cells 3 times with tab water. Staining was resolved with
10% Cetylpyridiumchloride solution and resulting optical densities
were measured at 562 nm [49]. Signals were normalized to
relative cell number determined by Alamar Blue conversion
(Biozol, Eching Germany).
RANKL ELISA
RANKL levels in culture supernatants were measured by
enzyme-linked immune-sorbent assay (ELISA) according to the
manufacturer’s protocol (Peprotech, London, UK).
Conventional RT-PCR
Total cellular RNA was isolated with Trifast (Peqlab, Erlangen,
Germany) according to the manufacturer’s protocol. First-strand
cDNA was synthesized from 1 mg total RNA using the
Transcriptor High Fidelity cDNA synthesis kit (Roche, Mann-
heim, Germany). Primer information are summarized in Table 2.
Products, resolved by gel electrophoresis in a 2% (w/v) agarose
gel, were visualized with ethidiumbromide. Densitometric analysis
of signals was performed using Image J software (NIH, Bethesda,
USA).
Statistics
Results are expressed as mean 6 standard deviation of at least 3
independent experiments (N$3) measured as triplicates or more
(n$3). Data sets were compared by one-way analysis of variance
(Kruskal-Wallis) followed by Dunn’s multiple comparison test
(GraphPad Prism Software, El Camino Real, USA). p,0.05 was
taken as minimum level of significance.
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